October 11, 2024

Poxel Announces Availability of the 2023 Universal Registration Document

LYON, France--(BUSINESS WIRE)-- Regulatory News:

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Universal Registration Document (Document d'Enregistrement Universel) for the year ended December 31, 2023, has been filed with the French market authority (Autorité des Marchés Financiers, or AMF).

This document is available in French on the AMF's website and on Poxel's website www.poxelpharma.com in the Investors / Shareholder Information / Regulatory Documentation section. A translation in English will be available later on the Company's website.

The 2023 Universal Registration Document includes:

- the 2023 Annual Financial Report, including the Management Report,
- the Report on Corporate Governance, and
- the Corporate Social Responsibility (CSR) Report.

Printed copies of the Universal Registration Document are also available to the public free of charge and upon request to the Company's headquarters located at Immeuble Le Sunway, 259-261 Avenue Jean Jaurès, 69007 Lyon, France.

About Poxel SA

Poxel is a **clinical stage biopharmaceutical company** developing **innovative treatments for chronic serious diseases with metabolic pathophysiology**, including **non-alcoholic steatohepatitis (NASH)** and rare disorders. For the treatment of NASH,**PXL065** (deuterium-stabilized *R*-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of **PXL770**, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). **TWYMEEG®** (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.

View source version on businesswire.com:
https://www.businesswire.com/news/home/20241010410531/en/

Investor relations / Media
NewCap
Nicolas Fossiez, Aurélie Manavarere / Arthur Rouillé
investor@poxelpharma.com
+33 1 44 71 94 94

Source: Poxel SA